- General Dermatology
- Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Anti-Aging
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
FDA approves dispenser for topical acne drug
The Food and Drug Administration has approved a pump dispenser for Galderma’s Differin (adapalene) Gel 0.3 percent, a retinoid indicated for the topical treatment of acne vulgaris in patients age 12 and older.
Washington - The Food and Drug Administration has approved a pump dispenser for Galderma’s Differin (adapalene) Gel 0.3 percent, a retinoid indicated for the topical treatment of acne vulgaris in patients age 12 and older.
Marketwire reports that the approval marks the first-ever pump dispenser for Differin Gel. The prescription pump will be available nationwide in the second quarter.
According to Marketwire, a recently completed preference survey involving 291 physician-diagnosed acne patients ages 12 to 35 ascertained patient preference for a pump delivery system of an adapalene-containing acne product versus a tube delivery system.
Go back to the Dermatology Times eNews newsletter.
